Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $1.48 --0%
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.00, $0.03 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $21.4 million versus the consensus estimate of $11.97 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Global chip stocks slide after Intel’s weak outlook
- Piper Sandler Companies (PIPR) Misses Q3 EPS by 6c, Misses on Revenue
- Goldman Sachs Upgrades Chow Tai Fook Jewellery Group Ltd. (1929:HK) (CJEWF) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
